Clinical trial · Observational
Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy
Added Value of Breast MRI in Evaluation of Pathologic Response in Patients With Locally Advanced Breast Cancer Who Undergo Neoadjuvent Chemotherapy
NCT05301790CI-TRIAL-00057412unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
evaluation of pathological response in breast mass by use of breast MRI in patients receiving neoadjuvent chemotherapy via comparison with pathological results
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Role of MRI in Evaluation of Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- comparison of MRI findings with pathologic results
- timeFrame
- baseline
- description
- added value of breast MRI in evaluation of pathologic response in patients with locally advanced breast cancer who undergo neoadjvent chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * all women referred to the radiology department for breast MRI examination either for screening, evaluation of suspicious lesions onsono-mammography \\ * Patients with locally advanced breast cancer * Patients with early stage breast cancer and chemo-responsive tumour markers (i.e. triple negative, Her2+), who will benefit from downsizing for breast conserving surgery (BCS) * Absolute or Relative contraindications to surgery (advanced age/multiple medical comorbidities) in the setting of estrogen receptor positive tumours (for consideration of neoadjuvant endocrine therapy)3 * Patients must be elder than 18 years old. * patients with accepted renal function Exclusion Criteria: * Patients with metastatic breast cancer. * Patient with breast mass more than 5 cm . * Patients with fungating breast mass . * Patients with stage IV \[tumor spread to chest wall and to skin \]. * pregnant women especially in 1th trimester. * Patient with presence of any paramagnetic substance as pacemakers. * severely ill patients . * patients with claustrophobia. * arrhythmic patients
References
Publications (0)
Data not yet available
No reference posted for this study.